46
Participants
Start Date
April 30, 2014
Primary Completion Date
October 31, 2016
Study Completion Date
August 31, 2018
HF10 plus Ipilimumab
Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Clinical Site, Hershey
Clinical Site, Bethlehem
Clinical Site, Atlanta
Clinical Site, Dallas
Clinical Site, Houston
Clinical Site, Salt Lake City
Clinical Site, San Francisco
Clinical Site, Portland
Collaborators (1)
Theradex
INDUSTRY
Takara Bio Inc.
INDUSTRY